Searching through a collection of 124 Staphylococcus aureus clinical strains, we found one isolate, strain 01A1032, that inactivates 14- and 16-membered macrolides. The products of inactivation were purified from supernatant fluids of cultures exposed to erythromycin for 3 h and were found to be identical to products of inactivation from Escherichia coli strains that encode either an EreA or EreB esterase. Further, strain 01A1032 was shown to be resistant to azithromycin, a 15-membered macrolide, by an alternate mechanism, efflux. Thus, strain 01A1032 harbors determinants encoding an esterase activity that hydrolyzes 14- and 16-membered macrolides and a macrolide efflux system.
1-Ethyl-3-(3-(dimethylamino)propyl)carbodiimide (EDC) bioconjugations have been utilized in preparing variants for medical research. While there have been advances in optimizing the reaction for aqueous applications, there has been limited focus toward identifying conditions and side reactions that interfere with product formation. We present a systematic investigation of EDC/N-hydroxysulfosuccinimide (sNHS)-mediated bioconjugations on carboxylated peptides and small proteins. We identified yet-to-be-reported side products arising from both the reagents and substrates. Model peptides used in this study illustrate particular substrates are more susceptible to side reactions than others. From our studies, we found that bioconjugations are more efficient with high concentrations of amine nucleophile but not sNHS. Performing bioconjugations on a model affibody protein show that the trends established with model peptides hold for more complex systems.
A novel series of substituted N-[3-(1,1,2,2-tetrafluoroethoxy)benzyl]-N-(3-phenoxyphenyl)-trifluoro-3-amino-2-propanols is described which potently and reversibly inhibit cholesteryl ester transfer protein (CETP). Starting from the initial lead 1, various substituents were introduced into the 3-phenoxyaniline group to optimize the relative activity for inhibition of the CETP-mediated transfer of [3H]-cholesteryl ester from HDL donor particles to LDL acceptor particles either in buffer or in human serum. The better inhibitors in the buffer assay clustered among compounds in which the phenoxy group was substituted at the 3, 4, or 5 positions. In general, small lipophilic alkyl, haloalkyl, haloalkoxy, and halogen moieties increased potency relative to 1, while analogues containing electron-donating or hydrogen bond accepting groups exhibited lower potency. Compounds with polar or strong electron-withdrawing groups also displayed lower potency. Replacement of the phenoxy ring in 1 with either simple aliphatic or cycloalkyl ethers as well as basic heteroaryloxy groups led to reduced potency. From the better compounds, a representative series 4a-i was prepared as the chirally pure R(+) enantiomers, and from these, the 4-chloro-3-ethylphenoxy analogue was identified as a potent inhibitor of CETP activity in buffer (4a, IC50 0.77 nM, 59 nM in human serum). The simple R(+) enantiomer 4a represents the most potent acyclic CETP inhibitor reported. The chiral synthesis and biochemical characterization of 4a are reported along with its preliminary pharmacological assessment in animals.
Matrix metalloproteinase-13 (MMP-13) is a zinc-dependent protease responsible for the cleavage of type II collagen, the major structural protein of articular cartilage. Degradation of this cartilage matrix leads to the development of osteoarthritis. We previously have described highly potent and selective carboxylic acid containing MMP-13 inhibitors; however, nephrotoxicity in preclinical toxicology species precluded development. The accumulation of compound in the kidneys mediated by human organic anion transporter 3 (hOAT3) was hypothesized as a contributing factor for the finding. Herein we report our efforts to optimize the MMP-13 potency and pharmacokinetic properties of non-carboxylic acid leads resulting in the identification of compound 43a lacking the previously observed preclinical toxicology at comparable exposures.
Thermolysis of a xylene solution of
Cp2Fe2(CO)4 and
PPh3 yields primarily
Cp4Fe4(CO)4 (1)
together
with smaller amounts of
(C5H4Ph)Cp3Fe4(CO)4
and
Cp3Fe3(CO)3(PPh2).
Cluster 1 can be alkylated and arylated
by using organolithium reagents to give the derivatives
(C5H4R)Cp3Fe4(CO)4.
This reaction is competitive
with reduction of 1 by the organolithium reagent. A
more versatile method for functionalizing 1 involves
its
deprotonation with lithium diisopropylamide (LDA) followed by treatment
with electrophiles to give
(C5H4X)Cp3Fe4(CO)4
(X = C(OH)HCH3, CO2H, CHO, SPh,
PPh2). An excess of LDA gave increased
amounts
of the di- and even trifunctionalized derivatives
(C5H4X)
x
Cp4
-
x
Fe4(CO)4
(x = 2, 3). Treatment of
(C5H4CHO)Cp3Fe4(CO)4 with
the lithiated cluster gave the double cluster
[(C5H4)Cp3Fe4(CO)4]2CHOH.
The use
of the cluster as a ligand was demonstrated by the synthesis of the
adducts
(C5H4PPh2ML
n
)Cp3Fe4(CO)4,
where ML
n
= RuCl2(cymene),
IrCl(1,5-C8H12). Single-crystal X-ray
diffraction was employed to characterize
[(C5H4)Cp3Fe4(CO)4]2CHOH
and
(C3H4PPh2)Cp3Fe4(CO)4RuCl2(cymene).
A novel series of substituted N-benzyl-N-phenyl-trifluoro-3-amino-2-propanols are described that reversibly inhibit cholesteryl ester transfer protein (CETP). Starting with screening lead 22, various structural features were explored with respect to inhibition of the CETP-mediated transfer of [(3)H]cholesterol from high-density cholesterol donor particles to low-density cholesterol acceptor particles. The free hydroxyl group of the propanol was required for high potency, since acylation or alkylation reduced activity. High inhibitory potency was also associated with 3-ether moieties in the aniline ring, and the highest potencies were exhibited by 3-phenoxyaniline analogues. Activity was substantially reduced by oxidation or substitution in the methylene of the benzylic group, implying that the benzyl ring orientation was important for activity. In the benzylic group, substitution at the 3-position was preferred over either the 2- or the 4-positions. Highest potencies were observed with inhibitors in which the 3-benzylic substituent had the potential to adopt an out of plane orientation with respect to the phenyl ring. The best 3-benzylic substituents were OCF(2)CF(2)H (42, IC(50) 0.14 microM in buffer, 5.6 microM in human serum), cyclopentyl (39), 3-iso-propoxy (27), SCF(3) (67), and C(CF(3))(2)OH (36). Separation of 42 into its enantiomers unexpectedly showed that the minor R(+) enantiomer 1a was 40-fold more potent (IC(50) 0.02 microM in buffer, 0.6 microM in human serum) than the major S(-) enantiomer 1b, demonstrating that the R-chirality at the propanol 2-position is key to high potency in this series. The R(+) enantiomer 1a represents the first reported acyclic CETP inhibitor with submicromolar potency in plasma. A chiral synthesis of 1a is reported.
Conjugate
vaccines prepared with the cross-reactive material 197
(CRM197) carrier protein have been successful in the clinic
and are of great interest in the field of immunotherapy. One route
to preparing peptide–CRM197 conjugate vaccines involves
an activation–conjugation strategy, effectively coupling lysine
residues on the protein to cysteine thiolate groups on the peptide
of interest using a heterobifunctional linker as an activation agent.
This method has been found to result in two distinct populations of
conjugates, believed to be the result of a conformational change of
CRM197 during preparation. This report explores the factors
that lead to this conformational change, pointing to a model in which
the unintentional alkylation of histidine-21 by the activating agent
promotes the “opening” of the monomeric protein. This
exposes a new set of lysine residues that are modified by additional
activation agents. Subsequent peptide ligation to these sites results
in the two conformers. This is the first time that a specific chemical
modification is demonstrated to induce a defined conformational change
for this carrier protein. Importantly, alternative conditions and
reagents have been found to minimize this effect, improving the conformational
homogeneity of peptide–CRM197 conjugates.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.